This 2021 review by Ard et al. examines the mechanisms, clinical efficacy, and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in obesity management. GLP-1RAs, initially developed for type 2 diabetes, promote weight loss by enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite through central nervous system pathways.
